Tempus Reports the US FDA’s Approval of Tempus ECG-AF to Detect Patients at Risk of Atrial Fibrillation
Shots:
- The US FDA has granted 510(k) clearance to the company’s AI-based Tempus ECG-AF device for detecting patients at high atrial fibrillation/flutter (AF) risk
- The Tempus ECG-AF algorithm analyzes 12-lead ECG recordings to identify atrial fibrillation (AF) symptoms within the next 12mos. It uses data gathered from patients (≥65yrs.) without a known history of AF or other specified conditions on resting 12-lead ECG recordings
- The data gathered is analyzed in combination with the patient’s original ECG recordings, other tests and clinical history
Ref: Tempus | Image: Tempus
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
